51ÖØ¿ÚÁÔÆæ

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: ).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Synthetic Immunology

Faculty of Medicine / Department of Laboratory Medicine / Division of Clinical Genetics

Visiting address: Sölvegatan 19, BMC C13, 221 84 Lund

Description

Genetically modified T cells, known as CAR T cells, function like cancer-targeting missiles, designed to specifically locate and eliminate tumor cells, providing promising prospects for more effective cancer therapies. While current iterations have demonstrated unprecedented success in certain blood cancers, they have proven ineffective in other cancer types, such as solid tumors and various blood cancers. This limitation primarily stems from the absence of truly cancer-specific antigens, markers on cancer cells that trigger the CAR-T response, posing challenges in targeting cancerous cells without causing harm to healthy tissues. We are pioneering the development of a new class of CAR-T cells capable of precisely identifying cancer cells expressing a combination of antigens, markedly enhancing their ability to discriminate and eradicate cancer cells while sparing normal tissues.

Staff

F

  • Ton Falqués

    Associate researcher

    ton [dot] falques [at] med [dot] lu [dot] se

H

J